Our Technology

Functionally Enhanced 

Natural Proteins


Darnatein leverages a unique synthetic biology platform enhanced by design-augmented AI to invent novel protein chimeras with superior efficacy compared to their natural parent ligands. We are currently focused on engineering improved BMPs (Bone Morphogenetic Proteins), key proteins involved in bone and cartilage healing. Existing BMP drugs require high doses, which can lead to significant local and systemic side effects. In contrast, Darnatein’s DA-BMPs are designed for greater therapeutic potency, enabling lower dosing and reducing the risk of adverse events.


Key advantages of Darnatein's technology:

- Natural BMPs require high therapeutic doses, which can cause side effects. DA-BMPs achieve superior effects at lower doses.

- The platform combines activities of known BMP family members into new constructs with superior activity and efficacy.
- Targeted protein design enhances efficacy while preserving low immunogenicity, reducing the risk of immune responses

- Integration of AI-augmented design enables continuous optimization and access to previously untargeted therapeutic pathways.




 Vision


Cares about people and health

Under the slogan ‘A Company That Cares for People and Health,’ we are accelerating the development of therapeutics, starting with treatments for musculoskeletal disorders and expanding into therapies for target diseases such as diabetes and obesity. The Biologics sector is a rapidly growing field worldwide, with an average annual market growth of over 20%. Compared to synthetic drugs, biologics have already been recognized in both academia and industry as more effective for treating severe diseases, with fewer side effects and greater safety.


Management


Management Philosophy and Management Goals


 Mechanism of Action

DRT-101: Design-augmented BMP-7/Activin chimeric protein for regeneration

DRT-101 is designed as a superagonist of the body’s natural regenerative pathways in joint cartilage. By augmenting the activity of endogenous growth factors such as BMPs, DRT-101 restores the balance between cartilage degradation and repair. This novel mechanism has the potential to modify the course of osteoarthritis, promoting true tissue regeneration rather than merely masking pain or inflammation.

- DRT-101 shows 30-fold higher activity compared to the natural ligand BMP-7
- DRT-101 beats BMP-7 on activation of pro-chodrocytic gene expression


DRT-102: Design-augmented BMP-2/Activin chimeric protein for bone fusion


DRT-102 extends the same design-augmented biology approach to degenerative spinal disorders. By enhancing local BMP signaling in intervertebral disc tissue, DRT-102 promotes extracellular matrix restoration and reduces inflammatory damage. Its engineered structure improves potency and stability while maintaining a low immunogenic profile, offering a new therapeutic avenue for chronic spine degeneration.

- DRT-102 shows superior effect and potency to BMP-2 in bone fusion model in animal studies (rodent and dog).

- DRT-102 shows clinically superior effect and potency to BMP-2 in human trials


Company Info



  • E-MAIL  ir@osr-holdings.com
  • Address  Building B 302, 30 Songdomirae-ro, Yeonsu-gu,  Incheon, Republic of Korea

Site Map 



Privacy Policy  I  Terms of Service
Copyright ⓒ Darnatein All rights reserved.